Available Technologies

Available Technologies 2016-11-17T13:59:40+00:00
Inventor: Volkhard Lindner, MD, PhD

Summary of Invention: The present invention features compositions and methods for treating and preventing a metabolic syndrome featuring the collagen triple helix repeat containing-1 (Cthrc1) protein.

Advantages:

Patent Application #: 20140011737

Patent Application Status: filed January 9, 2014

For more information contact:
Todd Keiller
Technology Transfer
Maine Medical Center
keillt@mmc.org

Inventors: Volkhard, Lindner, MD, PhD; Ilka Pinz, PhD; et al

Summary of Invention: The invention provides methods for the treatment of coronary heart disease, peripheral vascular disease, stroke, and ischemia featuring agents that interfere with the expression or activity of Cthrc1. The invention also provides the use of Cthrc1 peptide as a therapeutic agent for the treatment of acute or chronic cardiac deficiencies. The invention further provides detection and monitoring of Cthrc1 peptide in blood or serum to assess or monitor cardiac function.

Advantages:

Patent Application #: 20130059786

Patent Application Status: filed March 7, 2013

For more information contact:
Todd Keiller
Technology Transfer
Maine Medical Center
keillt@mmc.org

Inventors: Peter Brooks, PhD; Leif Oxburgh, DVM, PhD; et al

Summary of Invention: The present invention features compositions featuring agents that bind to denatured collagen and methods of using such agents to treat or prevent fibrosis or inflammation in a subject. 

Advantages:

Patent Application #: 20120237504

Patent Application Status: filed September 20, 2012

For more information contact:
Todd Keiller
Technology Transfer
Maine Medical Center
keillt@mmc.org

Inventor: Peter Brooks, PhD, et al.

Summary of Invention:  The present invention relates to the treatment of cancer using the sodium salt of a derivative of p-amino-benzoic acid (PABA). The invention also relates to the potentiation of radiotherapy, chemotherapy, or a combination thereof, with the sodium salt of the PABA derivative.  The present invention provides a method of treating cancer, comprising administering an effective amount of the sodium salt of the benzoic acid derivative C-45, wherein C-45 has the following Formula I: ##STR00001##.  In one embodiment, the sodium salt of C-45 is administered as monotherapy. In another embodiment, the sodium salt of C-45 is administered in combination with chemotherapy and/or radiation therapy. In one aspect of the invention, the cancer is melanoma. In another aspect of the invention, the cancer is breast carcinoma. In a further aspect of the invention, the cancer is lung carcinoma.

Advantages:

Patent #: 8,710,099

Patent Status:  issued April 29, 2014

For more information contact:
Todd Keiller
Technology Transfer
Maine Medical Center
keillt@mmc.org

Inventor: Lucy Liaw, PhD; et al.

Summary of Invention: The present invention relates to reagents and methods for the detection of osteopontin fragments and distinguishing them from each other and from the full-length osteopontin protein. The present invention also relates to assays for the determination of the presence of osteopontin fragments in samples obtained from subjects and, further, the correlation of osteopontin fragment levels with disease detection, progression and prognosis. 

Advantages:

Patent #: 8,399,207

Patent Status: issued March 19, 2013

For more information contact:
Todd Keiller
Technology Transfer
Maine Medical Center
keillt@mmc.org

Inventor: Don Wojchowski, PhD

Summary of Invention: The present invention relates to the generation of a novel population of Epo-responsive marrow derived cells that express Epo-responsive genes and gene products. Said novel population of Epo-responsive marrow derived cells are generated by isolating a subset of bone marrow cells that are, in one embodiment, Kit.sup.posCD71.sup.high, then culturing the Kit.sup.posCD71.sup.high cells in the absence of Epo or in the absence of hematopoietic cytokines (including Epo) for a period of time sufficient to substantially decrease Epo receptor signaling and then exposing them to Epo for a period of time sufficient to permit the expression of Epo-responsive genes. The present invention also relates to the detection of Epo-responsive genes and gene products. Further, the present invention relates to the detection of the administration of Epo, Epo-derivatives and Epo-mimetics in subjects based on the detection of expression of Epo-responsive genes.

Advantages:

Patent #: 8,349,559

Patent Status: issued January 8, 2013

For more information contact:
Todd Keiller
Technology Transfer
Maine Medical Center
keillt@mmc.org

Inventor: Douglas B. Spicer, PhD

Summary of Invention:  The present invention relates to compositions and methods for the modulation of metastatic and mesenchymal cell growth and mobility via the regulation of the formation of Twist/Twist homodimers and Twist/E heterodimers or their upstream or down stream effector molecules. The present invention also relates to methods for screening agents and compound libraries for molecules that function to modulate the formation of Twist/Twist homodimers, Twist/E protein heterodimers or their upstream or downstream effector molecules.

Advantages:

Patent #: 8,173,613

Patent Status: issued May 8, 2012

For more information contact:
Todd Keiller
Technology Transfer
Maine Medical Center
keillt@mmc.org

Inventor: Lucy Liaw, PhD

Summary of Invention: The invention includes a method of inhibiting the growth of a breast cancer cell in a mammal having breast cancer, comprising administering to a mammal an isolated polypeptide comprising an intracellular domain of Notch 2, or a biologically active mutant, variant or fragment thereof, wherein the polypeptide inhibits the growth of a breast cancer cell. In an aspect, the polypeptide is human Notch 2 intracellular domain (hNotch2ICD). 

Advantages:

Patent #: 7,700,113

Patent Status: issued April 20, 2010

For more information contact:
Todd Keiller
Technology Transfer
Maine Medical Center
keillt@mmc.org

Inventor: Jeong Kyo Yoon, PhD

Summary of Invention: The present invention relates to novel nucleotide sequences and the proteins encoded therein. The novel nucleotide sequences and proteins play a role in the Wnt signaling pathway. The Wnt signaling pathway is one of the key pathways in controlling cell proliferation, differentiation and morphogenesis. Breakdown of this pathway results in various disease states including tumorigenesis. The nucleotide sequences of the present invention encode a novel protein named Cristin1/R-spondin3. Cristin1/R-spondin3 is a cysteine-rich, secreted protein with an affinity to heparin. Although the present invention is not limited by theory or mechanism in any way, these proteins have been shown in the present invention to function as Frizzled/LRP6 receptor ligands and to induce the canonical Wnt/.beta.-catenin signal pathway leading to TCF-dependent gene activation. 

Advantages:

Patent #: 7,541,431

Patent Status: issued June 2, 2009

For more information contact:
Todd Keiller
Technology Transfer
Maine Medical Center
keillt@mmc.org

Inventors: Igor Prudovsky, PhD; Thomas Maciag, PhD; et al.

Summary of Invention: This invention relates to therapeutic and diagnostic methods and compositions based on Jagged/Notch proteins and nucleic acids, and on their role in the signaling pathway relating to endothelial cell migration and/or differentiation. In addition, this invention provides a substantially purified Jagged protein, as well as a substantially purified nucleic acid or segment thereof encoding Jagged protein, or a functionally equivalent derivative, or allelic or species variant thereof. Further, this invention provides a substantially purified soluble Jagged protein and a substantially purified nucleic acid encoding same as well as a recombinant cell comprising a nucleic acid encoding a soluble Jagged protein. Soluble Jagged provides further therapeutic and diagnostic methods relating to diseases, disorders, and conditions involving Jagged/Notch signaling including, inter alia, angiogenesis, differentiation, and control of gene expression. 

Advantages:

Patent #: 7,304,138

Patent Status: issued December 4, 2007

For more information contact:
Todd Keiller
Technology Transfer
Maine Medical Center
keillt@mmc.org

Inventors: Calvin Vary, PhD; et al.

Summary of Invention: Stable reference nucleic acid for use in all steps of molecular screening and diagnostic assays and method of making. A desired nucleic acid sequence is amplified, ligated into an expression vector, and used to transform a vehicle. A cellular vehicle is subsequently killed without affecting the encapsulated nucleic acid. The vehicle membrane is stabilized under controlled conditions to a stability substantially matching that of a test cell membrane. The recovered nucleic acid is used as a standard or control in molecular diagnostic and genetic testing assays.

Advantages:

Patent #: 6,074,825

Patent Status: issued June 13, 2000

For more information contact:
Todd Keiller
Technology Transfer
Maine Medical Center
keillt@mmc.org

Inventor: Igor Prodovosky, Thomas Maciag, et. al.

Summary of Invention: The inventors have discovered that non-traditional export of certain pro-inflammatory cytokines lacking a signal sequence from a cell can be inhibited by copper chelation. Copper chelation inhibits neointima formation, macrophage infiltration and associated inflammation, cell proliferation, secretion of extracellular matrix, intimal thickening, adventitial angiogenesis, restenosis, and vascular vessel injury in general. This invention describes a unique way of managing Interleukin-1 and FGF activity at the cellular level, which leads to the opportunity for a variety of therapeutic benefit. In vivo data has been generated and is available under a confidentiality agreement.

Advantages: This invention provides novel methods for preventing and treating various vessel injury diseases

Patent Status: Patent application, 8/24/01

For more information contact:
Todd Keiller
Technology Transfer
Maine Medical Center
keillt@mmc.org